

ABSTRACT OF THE DISCLOSURE

Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life *in vivo*. The selected peptides include 5 fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.

00020062225500